PALADIN LABS INC | 33,488 Euro | -0,217 -0,64 % | |
| WKN: 873464 ISIN: CA6959421026 Ticker-Symbol: 5PL | Frankfurt | 10.02.12 | 15:38 Uhr |
Branche PharmaAktienmarkt Sonstige |
|
| Zeit | Aktuelle Nachrichten | Leser | Medien | |
|---|---|---|---|---|
| 09.02. | Notice of Paladin Labs' Fourth Quarter 2011 Results Conference Call | 38 | MarketWire | |
| MONTREAL, CANADA -- (Marketwire) -- 02/09/12 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, will release its fourth quarter 2011 financial results on Thursday... Mehr lesen zu: Notice of Paladin Labs' Fourth Quarter 2011 Results Conference Call | ||||
| 09.02. | IMMURON LIMITED - Clarification ot terms of Debenture with Paladin Labs Inc. | - | wotnews | |
| 12.12. | Paladin Labs Announces the Canadian Launch of DigiFab(TM) Digoxin Immune Fab (Ovine) | 28 | MarketWire | |
| MONTREAL, CANADA -- (Marketwire) -- 12/12/11 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, announced today the Canadian launch of DigiFab Digoxin Immune Fab... Mehr lesen zu: Paladin Labs Announces the Canadian Launch of DigiFab(TM) Digoxin Immune Fab (Ovine) | ||||
| 27.10. | Notice of Paladin Labs' Third Quarter 2011 Results Conference Call | 15 | MarketWire | |
| MONTREAL, CANADA -- (Marketwire) -- 10/27/11 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, will release its third quarter 2011 financial results on Thursday... Mehr lesen zu: Notice of Paladin Labs' Third Quarter 2011 Results Conference Call | ||||
| 07.10. | Paladin Labs Completes Acquisition of Labopharm | 88 | MarketWire | |
| MONTREAL, CANADA -- (Marketwire) -- 10/07/11 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced that it has completed its previously announced acquisition... Mehr lesen zu: Paladin Labs Completes Acquisition of Labopharm | ||||
| 05.10. | Labopharm Inc. Shareholders Vote to Approve Acquisition by Paladin Labs Inc. | 91 | MarketWire | |
| MONTREAL, QUEBEC and LAVAL, QUEBEC -- (Marketwire) -- 10/05/11 -- Paladin Labs Inc. ("Paladin")(TSX: PLB) and Labopharm Inc. ("Labopharm")(TSX: DDS) today announced that at the Special Meeting of... Mehr lesen zu: Labopharm Inc. Shareholders Vote to Approve Acquisition by Paladin Labs Inc. | ||||
| 03.10. | Paladin Labs Advises That A Condition of Its Offer for Afexa Life Sciences Cannot Be Fulfilled / - No Shares Will Be Taken Up | 47 | MarketWire | |
| MONTREAL, CANADA -- (Marketwire) -- 10/03/11 -- Paladin Labs Inc. ("Paladin" or the "Company") (TSX: PLB), a leading Canadian diversified specialty pharmaceutical company, today announced it will... Mehr lesen zu: Paladin Labs Advises That A Condition of Its Offer for Afexa Life Sciences Cannot Be Fulfilled / - No Shares Will Be Taken Up | ||||
| 27.09. | Paladin Labs Confirms Enhanced $0.81 per Share Offer to Acquire Afexa Life Sciences / - Regulator has cease-traded Afexa Rights Plans - Choice of $0.81 in cash or 0.0217 of a Paladin share per Afexa share - Offer remains for any and all Afexa shares | 110 | MarketWire | |
| MONTREAL, CANADA -- (Marketwire) -- 09/26/11 -- Paladin Labs Inc. ("Paladin" or the "Company")(TSX: PLB), a leading Canadian diversified specialty pharmaceutical company, today confirmed that it is... Mehr lesen zu: Paladin Labs Confirms Enhanced $0.81 per Share Offer to Acquire Afexa Life Sciences / - Regulator has cease-traded Afexa Rights Plans - Choice of $0.81 in cash or 0.0217 of a Paladin share per Afexa share - Offer remains for any and all Afexa shares | ||||
| 26.09. | Paladin Labs Announces Proposed Increased Offer to Acquire Afexa Life Sciences for $0.81 per Share / - Increased offer will be made upon cease-trade of Afexa Rights Plans - 14% premium to the Valeant bid - Choice of $0.81 in cash or 0.0217 of a Palad | 166 | MarketWire | |
| MONTREAL, CANADA -- (Marketwire) -- 09/25/11 -- Paladin Labs Inc. ("Paladin" or the "Company") (TSX: PLB), a leading Canadian diversified specialty pharmaceutical company, today announced that, subject... Mehr lesen zu: Paladin Labs Announces Proposed Increased Offer to Acquire Afexa Life Sciences for $0.81 per Share / - Increased offer will be made upon cease-trade of Afexa Rights Plans - 14% premium to the Valeant bid - Choice of $0.81 in cash or 0.0217 of a Palad | ||||
| 23.09. | UPDATE 3-Paladin Labs to sweeten Afexa bid | - | Reuters.com | |
| 22.09. | Paladin Labs Announces Intention to Enhance Offer for Afexa Life Sciences | 25 | MarketWire | |
| MONTREAL, CANADA -- (Marketwire) -- 09/22/11 -- Paladin Labs Inc. ("Paladin" or the "Company") (TSX: PLB), a leading Canadian diversified specialty pharmaceutical company, today provided an update... Mehr lesen zu: Paladin Labs Announces Intention to Enhance Offer for Afexa Life Sciences | ||||
| 15.09. | Paladin Labs Extends Offer for Afexa Life Sciences / Offer now expires on September 28, 2011 | 24 | MarketWire | |
| MONTREAL, CANADA -- (Marketwire) -- 09/15/11 -- Paladin Labs Inc. ("Paladin" or the "Company") (TSX: PLB), a leading Canadian diversified specialty pharmaceutical company, today announced that it... Mehr lesen zu: Paladin Labs Extends Offer for Afexa Life Sciences / Offer now expires on September 28, 2011 | ||||
| 06.09. | Paladin Labs Inc. Issues Update Regarding Jonathan Ross Goodman | 7 | MarketWire | |
| MONTREAL, CANADA -- (Marketwire) -- 09/06/11 -- Paladin Labs Inc. ("Paladin" or the "Company") (TSX: PLB), a leading Canadian specialty pharmaceutical company, today provided an update on Mr. Jonathan... Mehr lesen zu: Paladin Labs Inc. Issues Update Regarding Jonathan Ross Goodman | ||||
| 30.08. | Paladin Labs Announces Distribution Agreement for OTC Women's Health Diagnostics | 34 | MarketWire | |
| MONTREAL, CANADA -- (Marketwire) -- 08/30/11 -- Paladin Labs Inc. ("Paladin")(TSX: PLB) a leading Canadian specialty pharmaceutical company, today announced that it has entered into a distribution... Mehr lesen zu: Paladin Labs Announces Distribution Agreement for OTC Women's Health Diagnostics | ||||
| 18.08. | UPDATE 1-Paladin Labs CEO out of action due to accident | - | Reuters.com | |
| 18.08. | Paladin Labs Inc. Issues Announcement Regarding Jonathan Ross Goodman | 79 | MarketWire | |
| MONTREAL, QUEBEC -- (Marketwire) -- 08/18/11 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced its President and CEO, Mr. Jonathan Ross Goodman... Mehr lesen zu: Paladin Labs Inc. Issues Announcement Regarding Jonathan Ross Goodman | ||||
| 17.08. | Labopharm Inc. Enters Into an Agreement to Be Acquired by Paladin Labs Inc. | 43 | MarketWire | |
| MONTREAL AND LAVAL, QUEBEC -- (Marketwire) -- 08/17/11 -- Paladin Labs Inc. ("Paladin")(TSX: PLB) and Labopharm Inc. ("Labopharm")(TSX: DDS) announced today that they have entered into a definitive... Mehr lesen zu: Labopharm Inc. Enters Into an Agreement to Be Acquired by Paladin Labs Inc. | ||||
Startseite • Nachrichten • Aktienkurse • Xetra-Orderbuch • Watchlist
Ad hoc-Mitteilungen • Chartanalysen • Nachrichten Börsen • Aktien-Empfehlungen
Branchen • Medien • Nachrichten-Archiv
Impressum | AGB | Disclaimer • Presse • Mediadaten
RSS-News von FinanzNachrichten.de kostenlos für Ihren Browser und Ihre Homepage
